The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia [PDF]
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh +4 more
doaj +3 more sources
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors [PDF]
Bruton tyrosine kinase (BTK) is involved in a multifarious inflammatory and autoimmune process. As a result, BTK has emerged as a promising novel remedial target for amalgamated autoimmune diseases.
Piyu Parth Naik
doaj +2 more sources
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy [PDF]
Background: Bruton tyrosine kinase (BTK) inhibitors (BTKi) have been proposed as therapy for thrombosis driven by immune complex activation of platelets via FcγRIIa.
Thomas Kartika +4 more
doaj +2 more sources
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies [PDF]
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical ...
Yuqin Song +18 more
doaj +2 more sources
High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies [PDF]
Not available.
Othman Al-Sawaf
doaj +2 more sources
Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter’s syndrome [PDF]
Richter’s syndrome (RS) is characterized by transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma.
Tristan Meier +4 more
doaj +2 more sources
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect [PDF]
Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has become a highly successful treatment modality for B-cell malignancies, especially for chronic lymphocytic leukaemia. However, long-term administration of BTKis
Haoran Wang +6 more
doaj +2 more sources
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies [PDF]
The effectiveness of Bruton tyrosine kinase (BTK) inhibitors is influenced by the level of BTK occupancy in target tissues. In randomized phase 3 studies, progression‐free survival (PFS) with zanubrutinib was superior to ibrutinib, whereas acalabrutinib ...
Oleg Demin Jr +10 more
doaj +2 more sources
Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe [PDF]
Advances in understanding the biology of chronic lymphocytic leukaemia (CLL) translated into revolutionary treatments with improved survival outcomes.
Igor Aurer +13 more
doaj +2 more sources
P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US) [PDF]
Bijal Shah +4 more
doaj +2 more sources

